Magnabiotic
Amoxicillin + Clavulanic Acid
1. Disclaimer
This monograph is provided for educational and informational purposes only and is not a substitute for the current official prescribing information, approved product leaflet, professional medical judgment, or advice from a qualified healthcare professional. Because formulations, approved indications, availability, regulatory status and prescribing information may change, the current Magnabiotic package insert and applicable Egyptian regulatory sources should be consulted before prescribing, dispensing or administering the product.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.
The information below describes Magnabiotic and the active combination amoxicillin/clavulanic acid and should not be interpreted as an individualized treatment recommendation. Antibiotics should be used only when clinically indicated and in accordance with applicable antimicrobial-stewardship principles.
2. Summary
Magnabiotic is a systemic antibacterial product containing amoxicillin, an aminopenicillin β-lactam antibiotic, combined with clavulanic acid, a β-lactamase inhibitor. The combination is designed to protect susceptible amoxicillin from degradation by certain bacterial β-lactamases and thereby extend its antibacterial activity.
SEDICO currently lists Magnabiotic among its systemic anti-infective products in oral suspension and tablet presentations. A recent SEDICO product list also documents oral strengths of 500 mg/125 mg and 875 mg/125 mg, suspension strengths of 125/31.25 mg, 200/30 mg, 250/62.5 mg and 400/60 mg per 5 mL, and intravenous strengths of 500/100 mg and 1000/200 mg per vial.
The combination is used for susceptible bacterial infections involving, among other sites, the ear, nose and throat, lower respiratory tract, urinary tract, skin and soft tissues, bones and joints, and intra-abdominal or female genital sites for appropriate intravenous formulations. The exact approved indications depend on the formulation and jurisdiction.
3. Brand Name
Magnabiotic
Manufacturer-associated brand: SEDICO Pharmaceutical Company / South Egypt Drug Industries Company (SEDICO).
SEDICO's current product website identifies Magnabiotic as a systemic anti-infective containing amoxicillin and clavulanic acid.
4. Category
- Therapeutic category: Systemic antibacterial
- Pharmacological class: Penicillin antibacterial + β-lactamase inhibitor
- ATC classification: J01CR02 — Combinations of penicillins, including β-lactamase inhibitors.
- Routes: Oral and intravenous, depending on formulation. The Egyptian Drug Authority antimicrobial formulary identifies amoxicillin/clavulanate as an oral and intravenous antibacterial combination.
5. Active Ingredient
Magnabiotic contains:
Amoxicillin + Clavulanic acid
The salt forms depend on the pharmaceutical form:
- Oral preparations: amoxicillin as amoxicillin trihydrate and clavulanic acid as potassium clavulanate.
- Intravenous preparations: amoxicillin as amoxicillin sodium and clavulanic acid as clavulanate potassium.
Clavulanic acid itself has little clinically useful antibacterial activity; its principal role is inhibition of susceptible β-lactamases that would otherwise hydrolyze amoxicillin.
6. Pharmaceutical Form & Strength
Magnabiotic has been documented in several oral and intravenous presentations.
Oral suspension
The documented strengths are:
| Strength per 5 mL | Amoxicillin | Clavulanic acid |
|---|---|---|
| 156.25 mg | 125 mg | 31.25 mg |
| 230 mg | 200 mg | 30 mg |
| 312.5 mg | 250 mg | 62.5 mg |
| 460 mg | 400 mg | 60 mg |
SEDICO's current product listing confirms these four suspension strengths.
Film-coated tablets
Current SEDICO documentation confirms:
- 625 mg: 500 mg amoxicillin + 125 mg clavulanic acid
- 1 g: 875 mg amoxicillin + 125 mg clavulanic acid.
Older Egyptian market records also document a 375 mg tablet corresponding to 250 mg amoxicillin + 125 mg clavulanic acid. However, this presentation is not listed on the current SEDICO systemic anti-infectives webpage retrieved during this review, so its present availability should be confirmed from the current Egyptian market listing or product pack.
Intravenous vials
Current SEDICO documentation identifies:
- 600 mg total: 500 mg amoxicillin + 100 mg clavulanic acid
- 1.2 g total: 1000 mg amoxicillin + 200 mg clavulanic acid
The latter may be referred to as a 1.2 g vial when the total combined active content is stated, whereas manufacturer listings may describe it by the amoxicillin component as a 1 g vial.
7. Manufacturer & Marketing Authorization Holder
Manufacturer:
South Egypt Drug Industries Company (SEDICO), Egypt.
SEDICO identifies itself as the company associated with Magnabiotic and lists its manufacturing/administrative location in the 6th of October industrial area, Giza, Egypt.
Marketing Authorization Holder:
SEDICO is the company identified with the Egyptian product documentation available for Magnabiotic. A separate current Egyptian regulatory document explicitly distinguishing the Egyptian MAH from the manufacturer was not located during this review; therefore, the safest formulation is to identify SEDICO as the product company/manufacturer and to avoid asserting a separate MAH entity without documentary confirmation.
8. Mechanism of Action
Amoxicillin is a semisynthetic penicillin belonging to the β-lactam antibacterial class. It inhibits bacterial cell-wall synthesis by binding to penicillin-binding proteins (PBPs) involved in peptidoglycan biosynthesis. Inhibition of peptidoglycan synthesis weakens the bacterial cell wall and can result in bacterial lysis and death.
Amoxicillin is vulnerable to hydrolysis by many bacterial β-lactamases. Clavulanic acid is structurally related to β-lactam antibiotics and inhibits several clinically relevant β-lactamases, thereby preventing destruction of amoxicillin and restoring activity against organisms whose resistance is mediated by susceptible β-lactamases.
Clavulanic acid does not itself provide clinically useful antibacterial activity when used alone. The principal pharmacodynamic driver of amoxicillin efficacy is the proportion of dosing time during which drug concentrations remain above the organism's MIC (T>MIC).
9. Spectrum of Activity
Amoxicillin/clavulanate has activity against a range of susceptible Gram-positive, Gram-negative and anaerobic bacteria, but the spectrum is not unlimited and must be interpreted in conjunction with local susceptibility data.
Organisms commonly susceptible to appropriately formulated co-amoxiclav preparations include:
- Gram-positive: Streptococcus pyogenes, other β-haemolytic streptococci, Streptococcus pneumoniae when susceptible, Enterococcus faecalis, methicillin-susceptible Staphylococcus aureus and selected coagulase-negative staphylococci.
- Gram-negative: Haemophilus influenzae, Moraxella catarrhalis, Pasteurella multocida, Eikenella corrodens, Capnocytophaga spp. and susceptible Enterobacterales.
- Anaerobes: Bacteroides fragilis, Fusobacterium spp. and Prevotella spp.
Resistance remains an important limitation. β-lactamases that are not inhibited by clavulanate, altered PBPs, reduced permeability and efflux mechanisms can confer resistance. Examples of organisms intrinsically resistant to this combination include Pseudomonas, Serratia, Stenotrophomonas, Acinetobacter, Morganella, Providencia and atypical respiratory organisms such as Mycoplasma pneumoniae and Chlamydophila spp.
Resistance prevalence varies with geography and time; local susceptibility data should therefore be considered when treating serious infections.
10. Pharmacokinetics
After oral administration, amoxicillin and clavulanic acid are rapidly and well absorbed. Current product information reports oral bioavailability of approximately 70% for both components, with peak concentrations generally occurring at approximately one hour.
Protein binding is relatively low: approximately 18% for amoxicillin and 25% for clavulanic acid. Both components distribute into several tissues and body fluids. After intravenous administration they have been detected in the gallbladder, abdominal tissues, skin, fat, muscle, synovial and peritoneal fluids, bile and pus. Amoxicillin does not achieve adequate cerebrospinal-fluid penetration in the absence of meningeal inflammation.
Amoxicillin is eliminated mainly by the kidneys. Clavulanic acid undergoes more extensive metabolism and is eliminated through both renal and non-renal routes. The mean elimination half-life of the combination is approximately one hour in healthy subjects.
For oral co-amoxiclav, approximately 60–70% of amoxicillin and 40–65% of clavulanic acid may be recovered unchanged in urine during the first six hours after selected single-dose studies; published 24-hour urinary excretion values vary according to formulation and study design.
Renal impairment reduces total clearance, with the effect generally more pronounced for amoxicillin. Dose adjustment is therefore important in significant renal dysfunction. Hepatic impairment also warrants caution and monitoring because of the hepatic component of clavulanate handling and the known hepatic adverse-effect profile of co-amoxiclav.
11. Indications
Depending on the formulation and approved local labeling, amoxicillin/clavulanic acid is used for treatment of susceptible bacterial infections including:
- Acute bacterial sinusitis.
- Acute otitis media.
- Acute exacerbations of chronic bronchitis when adequately diagnosed.
- Community-acquired pneumonia.
- Cystitis and pyelonephritis.
- Skin and soft-tissue infections, including cellulitis, animal bites and severe dental abscess with spreading cellulitis.
- Bone and joint infections, particularly osteomyelitis.
Intravenous formulations additionally have approved uses in severe ear, nose and throat infections, intra-abdominal infections and female genital infections, as well as perioperative prophylaxis for selected major surgical procedures according to the applicable product information.
The older supplied text listed broader terms such as "gonorrhea," "emphysema," "septicemia" and "enteritis." These terms should not be retained as generic blanket indications without formulation-specific regulatory support. Current product information emphasizes defined bacterial syndromes and recommends adherence to official antibacterial-use guidance.
12. Administration
Oral preparations
Oral Magnabiotic should be administered exactly according to the current product-specific prescribing information.
For co-amoxiclav formulations containing the 7:1 ratio such as 875 mg/125 mg, current prescribing information commonly recommends administration with a meal to minimize gastrointestinal intolerance.
The various Magnabiotic strengths are not therapeutically interchangeable on a milligram-for-milligram basis, because they contain different amoxicillin-to-clavulanate ratios. In particular, the 625 mg tablet (500/125 mg) and the 1 g tablet (875/125 mg) should not be treated as equivalent formulations.
Representative current 7:1 co-amoxiclav dosing for adults and children weighing ≥40 kg is 875/125 mg twice daily, with 875/125 mg three times daily used for selected infections where a higher exposure is appropriate. Children weighing <40 kg are generally dosed according to body weight and formulation.
Intravenous preparations
Intravenous co-amoxiclav is administered by slow IV injection or IV infusion. It is not suitable for intramuscular administration. A current 1000/200 mg IV product specifies slow IV injection over approximately 3–4 minutes or infusion over 30–40 minutes.
The exact dose and interval depend on infection severity, age/weight and renal function. For one current 1000/200 mg IV formulation, adults and children ≥40 kg receive 1000/200 mg every 8 hours for indicated infections, while pediatric dosing is weight-based.
Treatment should generally be reviewed if prolonged beyond 14 days unless a specific clinical justification exists.
13. Method of Preparation
Oral suspension
The powder for oral suspension must be reconstituted with the specified quantity of water according to the current Magnabiotic bottle/leaflet instructions. The bottle should be shaken thoroughly after the appropriate additions of water and shaken again before every dose.
Because reconstitution volumes and in-use stability may be product- and formulation-specific, the current Magnabiotic package instructions should take precedence over generic co-amoxiclav instructions.
The supplied historical Magnabiotic text stated a 7-day refrigerated period after reconstitution. A seven-day refrigerated period is also used for some currently authorized amoxicillin suspension products, but this cannot automatically be assumed for every co-amoxiclav formulation. Therefore, the current Magnabiotic package insert should be followed for the specific strength.
Intravenous vials
IV preparation must be performed aseptically and strictly according to the current product-specific instructions.
For a current 500/100 mg co-amoxiclav IV product, 10 mL Water for Injection is used for reconstitution, producing approximately 10.4 mL of solution, followed by administration within the specified short in-use period. The reconstituted solution is intended for immediate use or prompt dilution, and the infusion is compatible with specified fluids such as Water for Injection and 0.9% sodium chloride.
A current 1000/200 mg product similarly requires immediate use or dilution after reconstitution and may be given by slow IV injection or infusion.
The exact reconstitution volume for Magnabiotic should always be confirmed from the current Magnabiotic vial label/package insert rather than inferred from another manufacturer's co-amoxiclav product.
14. Contraindications
Magnabiotic/amoxicillin-clavulanate is contraindicated in patients with:
- Hypersensitivity to amoxicillin, clavulanic acid, penicillins or relevant excipients.
- A history of severe immediate hypersensitivity reactions, such as anaphylaxis, to other β-lactam antibiotics including relevant cephalosporins, carbapenems or monobactams.
- A previous history of jaundice or hepatic impairment associated with amoxicillin/clavulanic acid.
The history of β-lactam allergy should therefore be carefully documented before therapy.
15. Warnings & Precautions
Important precautions include:
- Serious hypersensitivity: Anaphylaxis and other severe hypersensitivity reactions can occur and may be life-threatening. Therapy must be discontinued if a significant allergic reaction develops.
- Severe cutaneous reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS and AGEP have been reported.
- Drug-induced enterocolitis syndrome (DIES): Reported mainly in children, characterized by delayed severe vomiting, sometimes accompanied by abdominal symptoms, diarrhea, hypotension and shock.
- Hepatic injury: Hepatitis and cholestatic jaundice are recognized adverse reactions. Hepatic events may appear during treatment or after treatment has ended.
- Antibiotic-associated colitis: Significant or persistent diarrhea during or after treatment may represent Clostridioides difficile-associated disease.
- Renal impairment: Dose adjustment is required according to renal function for applicable formulations.
- Crystalluria/acute kidney injury: Rarely reported, particularly with high-dose parenteral therapy; adequate hydration and urinary output are important in appropriate clinical settings.
- Infectious mononucleosis: Amoxicillin-containing therapy should generally be avoided when infectious mononucleosis is suspected because a characteristic morbilliform rash can occur.
- Prolonged treatment: May promote overgrowth of non-susceptible organisms and warrants periodic assessment of renal, hepatic and hematologic function when clinically appropriate.
- Laboratory interference: Amoxicillin may interfere with some urinary glucose tests, and clavulanic acid may cause a false-positive direct Coombs test. False-positive results have also been reported with certain Aspergillus antigen assays.
- IV formulation: Some IV presentations contain clinically relevant sodium and potassium quantities, which may matter in patients on controlled electrolyte intake or with relevant renal disease.
16. Drug Interactions
Important clinically relevant interactions include:
Oral anticoagulants
Concurrent use with warfarin or acenocoumarol may be associated with increased INR/prothrombin time in some patients. Close monitoring is recommended when co-amoxiclav is initiated or discontinued, with anticoagulant dose adjustment when necessary.
Methotrexate
Penicillins may reduce methotrexate excretion and potentially increase methotrexate toxicity. Appropriate clinical monitoring is therefore required.
Probenecid
Probenecid decreases renal tubular secretion of amoxicillin and may produce increased and prolonged amoxicillin concentrations. Concurrent use is generally not recommended.
Mycophenolate mofetil
Oral amoxicillin/clavulanate has been associated with approximately 50% reduction in the pre-dose concentration of mycophenolic acid in some patients. Clinical monitoring is recommended, although automatic mycophenolate dose adjustment is not generally required without evidence of graft dysfunction.
Allopurinol
Concomitant allopurinol therapy during amoxicillin treatment may increase the likelihood of skin reactions.
The historical Magnabiotic statement that co-amoxiclav routinely reduces the efficacy of oral contraceptives is not appropriate as a blanket interaction statement. The principal concern is contraceptive failure associated with vomiting/diarrhea or other specific circumstances rather than a demonstrated universal pharmacokinetic reduction in contraceptive efficacy. The current interaction information should therefore be consulted for the individual patient.
17. Side Effects
The most commonly reported adverse effects are diarrhea, nausea and vomiting.
Other possible adverse reactions include:
- Abdominal discomfort or indigestion.
- Mucocutaneous candidiasis.
- Headache or dizziness.
- Skin rash, pruritus and urticaria.
- Elevated AST/ALT.
- Hepatitis and cholestatic jaundice.
- Reversible leukopenia, thrombocytopenia and other hematologic abnormalities.
- Anaphylaxis and angioedema.
- Antibiotic-associated colitis.
- Severe cutaneous reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS and AGEP.
- Interstitial nephritis and crystalluria.
- Convulsions, particularly in patients with renal impairment or receiving high doses.
- Rare neurological or hematologic reactions.
Persistent severe diarrhea, jaundice, marked rash, mucosal lesions, breathing difficulty, facial swelling, severe vomiting or other serious symptoms require prompt medical evaluation.
18. Use in Special Populations
Pregnancy
Current evidence does not indicate a general increased risk of congenital malformations with amoxicillin/clavulanic acid. However, an association with neonatal necrotizing enterocolitis has been reported in a study involving prophylactic treatment after preterm premature rupture of fetal membranes. Consequently, use during pregnancy should be based on an appropriate benefit-risk assessment rather than routinely avoided or routinely assumed safe.
The historical statement that Magnabiotic "should be avoided during pregnancy, especially during the first trimester" is therefore too categorical and is not retained in this form.
Breastfeeding
Amoxicillin and small amounts of clavulanic acid are excreted into breast milk. Possible effects include diarrhea, mucosal fungal infection or sensitization in the breastfed infant. Clinical benefit-risk assessment is appropriate.
Pediatrics
Children should generally receive a formulation and dose appropriate to body weight and age. Pediatric dosing differs according to the amoxicillin-to-clavulanate ratio and formulation. Some current 7:1 presentations have specific weight-based recommendations, whereas these cannot simply be transferred to all Magnabiotic strengths.
Elderly
No routine age-based adjustment is required solely because of age, but renal function should be considered because declining renal function is more common in older adults.
Renal impairment
Dosage adjustment may be required according to creatinine clearance and formulation. Amoxicillin clearance falls with declining renal function, making accumulation clinically relevant.
Hepatic impairment
Use with caution and monitor hepatic function when clinically appropriate. A previous history of jaundice/hepatic impairment attributed to amoxicillin/clavulanate is a contraindication.
19. Storage Conditions
Tablets
Storage conditions are product-specific. Current co-amoxiclav film-coated tablet information commonly specifies storage not above 25°C, protected in the original packaging from moisture and light.
Powder for oral suspension
The dry powder should be stored according to the current Magnabiotic package labeling, generally in a dry environment at the temperature specified on the pack.
After reconstitution, the suspension should be stored according to the specific Magnabiotic strength's current instructions. Refrigeration at 2–8°C is used for many amoxicillin-containing suspensions, but the exact validated in-use period must not be extrapolated from another formulation.
Intravenous vials
Unreconstituted IV vials should be stored according to their specific product labeling. Current co-amoxiclav IV products may specify storage at temperatures not above 25°C. After reconstitution, stability is short and formulation-dependent; solutions are generally intended for immediate or prompt use.
Keep all medicines out of the reach of children.
20. Additional Sections
Antimicrobial stewardship
Magnabiotic should be reserved for infections in which bacterial treatment with amoxicillin/clavulanate is clinically appropriate. The combination should not be used simply because a broad-spectrum antibiotic is desired. Where a pathogen is known to be adequately susceptible to amoxicillin alone, stewardship principles support considering the narrower agent when clinically appropriate.
Dosing and formulation caution
A major practical point is that Magnabiotic includes formulations with different amoxicillin-to-clavulanate ratios. 375 mg, 625 mg, 1 g tablets and the various suspension strengths must not be treated as interchangeable simply because their total labeled milligram quantities appear similar.
For example:
- 375 mg tablet = 250 mg amoxicillin + 125 mg clavulanic acid.
- 625 mg tablet = 500 mg amoxicillin + 125 mg clavulanic acid.
- 1 g tablet = 875 mg amoxicillin + 125 mg clavulanic acid.
- 600 mg IV vial = 500 mg amoxicillin + 100 mg clavulanic acid.
- 1.2 g IV vial = 1000 mg amoxicillin + 200 mg clavulanic acid.
Overdose
Overdose may produce gastrointestinal symptoms and fluid/electrolyte disturbance. Amoxicillin crystalluria, acute renal injury and seizures are more important concerns in severe overdose or renal impairment. Amoxicillin/clavulanic acid can be removed by hemodialysis.
Current Egyptian market documentation
SEDICO's currently accessible website lists the following Magnabiotic products:
- Magnabiotic 156.25 mg suspension
- Magnabiotic 230 mg suspension
- Magnabiotic 312.5 mg suspension
- Magnabiotic 460 mg suspension
- Magnabiotic 625 mg tablets
- Magnabiotic 1 g tablets
SEDICO's recent product-list documentation additionally identifies:
- 500/125 mg tablets
- 875/125 mg tablets
- 500/100 mg IV vial
- 1000/200 mg IV vial
- the four oral-suspension strengths above.
Older Egyptian market records also document 375 mg tablets and a 600 mg vial. Because these presentations are not all displayed on the currently accessible SEDICO product webpage, their current retail availability should be checked against the live Egyptian market rather than assumed from historical records.
21. Frequently Asked Questions (FAQ)
What is Magnabiotic?
Magnabiotic is a brand of amoxicillin plus clavulanic acid, a β-lactam antibacterial combination used against susceptible bacterial infections.
Is Magnabiotic a broad-spectrum antibiotic?
It has broader activity than amoxicillin alone against organisms producing certain β-lactamases, but it is not universally active against all resistant bacteria. Its usefulness depends on the pathogen, site of infection and local resistance patterns.
What is the difference between Magnabiotic 625 mg and 1 g?
Magnabiotic 625 mg contains 500 mg amoxicillin + 125 mg clavulanic acid, whereas Magnabiotic 1 g contains 875 mg amoxicillin + 125 mg clavulanic acid. They should not be regarded as dose-equivalent products.
Can Magnabiotic tablets and suspension be substituted freely?
No. Different strengths have different amoxicillin/clavulanate ratios and concentrations. Substitution requires calculation and reference to the appropriate formulation-specific prescribing information.
Can Magnabiotic be given intramuscularly?
The intravenous co-amoxiclav formulations described in current product information are not suitable for intramuscular administration.
Should Magnabiotic be taken with food?
For many oral co-amoxiclav formulations, administration with a meal is recommended to reduce gastrointestinal intolerance. The specific current Magnabiotic product instructions should be followed.
Is Magnabiotic effective against viral infections?
No. Amoxicillin/clavulanic acid is an antibacterial combination and has no therapeutic activity against ordinary viral respiratory infections.
Can Magnabiotic cause diarrhea?
Yes. Diarrhea is among the most common adverse effects. Severe or persistent diarrhea during or after antibiotic treatment requires medical assessment because antibiotic-associated colitis, including C. difficile-associated disease, is possible.
Can Magnabiotic cause liver problems?
Yes. Elevated liver enzymes, hepatitis and cholestatic jaundice have been reported. Hepatic injury may occasionally become apparent after treatment has ended.
Can Magnabiotic be used during pregnancy?
Pregnancy does not represent an automatic contraindication. Available human data do not show a general increase in congenital malformations, but treatment should be used when clinically indicated after appropriate benefit-risk assessment.
Can Magnabiotic be used during breastfeeding?
Both components enter breast milk in small amounts. It may be used when clinically appropriate after consideration of benefits and possible effects in the infant.
Does Magnabiotic interact with methotrexate or warfarin?
Yes. Penicillins may increase methotrexate toxicity by reducing its excretion, while warfarin or similar anticoagulants may require closer INR/prothrombin-time monitoring.
22. References
- SEDICO Pharmaceutical Company. Systemic Anti-infectives — Magnabiotic product listings. Current manufacturer website.
- SEDICO / CPHI. SEDICO Product List 2025 — Magnabiotic strengths and pack information.
- Egyptian Drug Authority (EDA). Antimicrobial Formulary — Amoxicillin and Clavulanic Acid, including dosage forms, routes, indications and pharmacological classification.
- Electronic Medicines Compendium (emc). Co-amoxiclav 875 mg/125 mg film-coated tablets — SmPC, updated December 2025. Mechanism, indications, dosing, contraindications, warnings, interactions, adverse effects and pharmacokinetics.
- Electronic Medicines Compendium (emc). Co-amoxiclav 1000 mg/200 mg powder for solution for injection/infusion — SmPC, updated March 2026. IV dosing, administration, warnings, interactions and special-population information.
- Electronic Medicines Compendium (emc). Co-amoxiclav 500 mg/100 mg powder for solution for injection/infusion — SmPC, updated January 2026. IV preparation, stability, spectrum and pharmacokinetics.
- Egyptian Drug Authority. Egyptian antimicrobial guidance and drug-information resources. The EDA states that its antimicrobial formulary is intended to provide updated information on drug classification, indications, doses, interactions, contraindications, adverse effects and storage.
- SEDICO / manufacturer-associated market documentation and historical Egyptian product listings were used only to distinguish currently documented presentations from older market records; historical availability was not treated as proof of current retail availability.
Evidence status: The scientific and safety sections above have been aligned with current 2025–2026 product information and Egyptian antimicrobial guidance where available. Brand-specific pack instructions, exact reconstitution volumes, validated in-use stability and current Egyptian authorization/availability should always be checked against the latest Magnabiotic package insert and current Egyptian Drug Authority records before use.